Biogen Inc (BIIB)
Biogen Inc (BIIB) carries a ŷRobot AI score of 71 out of 100. The model's fair value estimate is $270.85, 6.9% above the last close of $253.40. The chart signal reads Sell.
| Metric | BIIB |
|---|---|
| AI score | 71 / 100 |
| Chart signal | Sell |
| Fair value estimate | $270.85 |
| Upside to fair value | 6.9% |
| Previous close | $253.40 |
| P/E | 43.35 |
| Price / sales | 3.68 |
| Market cap | $37.03B |
| EPS | 5.63 |
| Revenue growth | -1.3% |
| 1-year price change | -2.9% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about BIIB
Is BIIB overvalued or undervalued right now?
As of Oct 30, 2026, ŷRobot's fair-value model estimates Biogen Inc (BIIB) at $270.85 against a last close of $253.40, implying 6.9% upside to the model's estimate.
Is BIIB's chart signal bullish or bearish?
The chart-signal model classifies BIIB as Neutral as of Nov 13, 2026, with a signal score of -0.13 on a -1 to 1 scale.
What is BIIB's ŷRobot AI score?
BIIB scores 71 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is BIIB stock expensive on P/E and P/S?
BIIB trades at 43.4 times earnings and 3.7 times sales as of Nov 13, 2026.
What does BIIB's seasonal forecast show?
ŷRobot's seasonal forecast curve for BIIB reads +0.9% at 30 days, +3.5% at 90 days, and -2.9% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is BIIB growing?
Biogen Inc's revenue growth is -1.3% and free-cash-flow growth is +6.5% on the latest reported figures.
BIIB chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.